AbbVie reported a strong second quarter, driven by Skyrizi, Rinvoq, and neuroscience products, and raised its full-year 2026 guidance. The company is preparing for potential new launches (Skyrizi subcutaneous induction, Tavapadon) and an imminent acquisition of Apogee Therapeutics to bolster its pipeline. Management remains confident in long-term growth targets. Q2 2026 revenue beat expectations by $300M and EPS by $0.06, driven by strong performance across the portfolio.
AbbVie reported a strong second quarter, driven by Skyrizi, Rinvoq, and neuroscience products, and raised its full-year 2026 guidance. The company is preparing for potential new launches (Skyrizi subcutaneous induction, Tavapadon) and an imminent acquisition of Apogee Therapeutics to bolster its pipeline. Management remains confident in long-term growth targets. Q2 2026 revenue beat expectations by $300M and EPS by $0.06, driven by strong performance across the portfolio.
AbbVie reported a strong second quarter, driven by Skyrizi, Rinvoq, and neuroscience products, and raised its full-year 2026 guidance. The company is preparing for potential new launches (Skyrizi subcutaneous induction, Tavapadon) and an imminent acquisition of Apogee…
Q2 2026 revenue beat expectations by $300M and EPS by $0.06, driven by strong performance across the portfolio.
Guidance · revenue to $67.6B
Skyrizi continues to capture significant new patient share and is nearing a potential US approval for subcutaneous induction in Crohn's disease.
Management raised full-year revenue and EPS guidance, indicating sustained strong momentum across key growth products, partly offset by anticipated (but non-core) near-term dilution from the Apogee acquisition.
Management repeatedly framed the quarter as overperformance, raised full-year guidance, and highlighted pipeline and M&A momentum as durable long-term growth drivers.
“we can actually see our raw MBRX data in the derm and psoriasis market... we've absolutely seen no degradation in any of our MBRX trends. In fact, they've actually grown from the launch of ICO in March.”
“45 points higher in patients who had not previously experienced advanced therapy. To our knowledge, these results in patients naive to advanced therapies are the highest reported for induction therapies in Crohn's disease”
“We are in parallel working on co-formulation, so the intent at launch for any of these assets in combination with Skyrizzy in IBD would be a co-formulation.”
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| EPS | FY2026 | $13.87–$14.07 | $13.97 | RAISED |
| Revenue | FY2026 | $67.6B | $67.6B | RAISED |
| Revenue | FY2026 Q3 | $17.2B | $17.2B | GUIDED |
| Issued | Metric | Target | Guide | Actual | Outcome |
|---|---|---|---|---|---|
| FY2026 Q1 | EPS | FY2026 Q2 | $3.74–$3.78 | $3.65 | Missed |
| FY2025 Q4 | EPS | FY2026 Q1 | $2.97–$3.01 | $2.65 | Missed |
| FY2025 Q4 | Revenue | FY2026 Q1 | $14.7B | $15.002B | Met / beat |
Acquisition target that AbbVie believes holds significant long-term potential in dermatology, respiratory, and other inflammatory diseases.
“our planned acquisition of Apogee Therapeutics, which represents an exciting opportunity to bolster AbbVie's leading immunology portfolio.”
Thank you, Liz. Good morning, everyone, and thank you for joining us. AVI delivered another excellent quarter, with results once again exceeding our expectations. I'm especially pleased with the execution across our business, including double-digit sales growth from our diverse portfolio, the advancement of our compelling pipeline of innovative medicines, and our planned acquisition of Apogee Therapeutics, which represents an exciting opportunity to bolster AbbVie's leading immunology portfolio. Turning to our second quarter performance, We achieved adjusted earnings per share of $3.65, which is six cents above our guidance midpoint. Total net revenues were nearly $17 billion, beating our expectations by $300 million and reflecting robust sales growth of 10.2%. The performance of SkyRizzy, Renvoke, and our neuroscience portfolio continues to be very strong. with each delivering growth above 20%. Based on this momentum, we are raising our full year revenue guidance by $300 million and have now raised total revenue by $600 million since the start of the year. Turning now to R&D, we continue to make excellent progress advancing our pipeline. Recent highlights from our late stage …
AbbVie has not seen any degradation in Skyrizi's new patient start share (total prescriptions) since the launch of a new oral competitor in March.